Skip to main content

and
  1. Article

    Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

    Yu Shi, Weina Gao, Nikki K. Lytle, Peiwu Huang, **ao Yuan, Amanda M. Dann in Nature (2021)

  2. Article

    Open Access

    Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer

    KRAS mutations are present in over 90% of pancreatic ductal adenocarcinomas (PDAC), and drive their poor outcomes and failure to respond to targeted therapies. Here we show that Leukemia Inhibitory Factor (LIF...

    Man-Tzu Wang, Nicole Fer, Jacqueline Galeas, Eric A. Collisson in Nature Communications (2019)

  3. No Access

    Article

    Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

    Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis largely owing to inefficient diagnosis and tenacious drug resistance. Activation of pancreatic stellate cells (PSCs) and consequent development of...

    Yu Shi, Weina Gao, Nikki K. Lytle, Peiwu Huang, **ao Yuan, Amanda M. Dann in Nature (2019)

  4. Article

    Open Access

    Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma

    Sebaceous carcinomas (SeC) are cutaneous malignancies that, in rare cases, metastasize and prove fatal. Here we report whole-exome sequencing on 32 SeC, revealing distinct mutational classes that explain both ...

    Jeffrey P. North, Justin Golovato, Charles J. Vaske in Nature Communications (2018)